Early post-procedural migraine attack predicts migraine resolution after patent foramen ovale transcatheter closure.
OBJECTIVE
In patients with patent foramen ovale-related migraine, the procedure of transcatheter closure itself is likely to cause a migraine attack. Our study is aimed to evaluate the incidence of migraine attacks immediately after closure procedure and their clinical and potential prognostic significance.


METHODS
We reviewed our database from January 2005 to April 2007 searching for patients with severe disabling migraine despite anti-headache therapy who were submitted to transcatheter closure of patent foramen ovale (PFO). Medical records of these patients were carefully reviewed in order to record migraine episodes immediately (0 to 6 h) after closure procedure.


RESULTS
Twenty-one patients with previous stroke and migraine underwent PFO closure: the procedure was successful in all of the patients with no perioperative and in-hospital complications. Ten patients (47.6%) experienced a migraine attack of mean duration 3.5+/-2.4 h immediately after the closure procedure. Those patients had the same procedure time compared with other patients, but had larger PFO: patients with migraine attack immediately after closure had higher rate of complete abolition of migraine in the follow-up.


CONCLUSIONS
Although more larger studies are needed to evaluate the exact relationships between migraine and PFO, in patients with a tight correlation between migraine and PFO, a prolonged opening of the PFO, as during closure procedure, may cause a migraine attack immediately after the closure. This fact can be considered a positive prognostic factor for migraine abolishment in the follow-up.
Rigatelli
G
G
Unit of Adult Congenital and Structural Heart Disease, Cardiovascular Diagnosis and Interventions, Department of Neurosciences, Rovigo General Hospital, Rovigo, Italy. jackyheart@hotmail.com
Cardaioli
P
P
Dell'Avvocata
F
F
Braggion
G
G
Giordan
M
M
Chinaglia
M
M
D000328:Adult; D006328:Cardiac Catheterization; D005260:Female; D054092:Foramen Ovale, Patent / Q000628:therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D008881:Migraine Disorders / Q000453:epidemiology*